Dayvigo Employer + ICHRA Coverage Navigation: How to Get Lemborexant Covered in 2026

What Is Dayvigo and Why Does Coverage Matter?

Dayvigo is a dual orexin receptor antagonist (DORA) approved by the FDA on December 20, 2019, for the treatment of insomnia characterized by difficulty with sleep onset or maintenance in adults [1]. Lemborexant works by blocking orexin OX1 and OX2 receptors, suppressing wake-promoting signaling rather than broadly suppressing the central nervous system the way older sedative-hypnotics do [2].

Clinical Efficacy at a Glance

The SUNRISE-2 trial (N=949, 12 months) demonstrated that lemborexant 5 mg and 10 mg both produced statistically significant improvements in subjective sleep onset latency and wake after sleep onset compared with placebo at six months, with a P<0.001 for both doses [3]. The FDA's summary basis of approval notes that the 10 mg dose reduced mean subjective sleep onset latency by approximately 23 minutes versus placebo after one month of treatment [1].

Because no generic exists, the branded cost sits at roughly $430, $490 per 30-day supply at most retail pharmacies in 2026. That price point makes coverage navigation the single biggest practical issue for most patients starting Dayvigo.

Why Employer Plans Often Restrict It

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline on chronic insomnia recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before any pharmacotherapy [4]. Most commercial formularies mirror that evidence hierarchy: they place Dayvigo on Tier 3 or Tier 4 and require documentation that a patient has tried at least one generic sleep aid (commonly trazodone, doxepin, or zolpidem) before approving a branded DORA [5].

Understanding that logic helps you build a stronger prior authorization (PA) package.

How Employer Insurance Plans Handle Dayvigo

Most group health plans cover Dayvigo, but almost always with conditions attached. The specific tier, co-pay, and step-therapy requirements vary by carrier and plan year.

Formulary Tiers and Typical Cost-Sharing

Dayvigo lands on Tier 3 ("preferred brand") or Tier 4 ("non-preferred brand") depending on the carrier. Tier 3 typically carries a co-pay of $50, $75 per fill after deductible; Tier 4 can reach $100, $150 or coinsurance of 25 to 40% of the negotiated price.

Suvorexant (Belsomra, also a DORA) is the only comparator in the same drug class. Some plans prefer Belsomra because Merck has negotiated rebates; others are agnostic. Confirming your specific plan's formulary before your prescriber writes the PA letter saves time [5].

Step Therapy: What You Have to Try First

Step therapy policies for Dayvigo typically require a documented trial of one or two of the following:

• Trazodone 50 to 100 mg (off-label, widely prescribed; no FDA insomnia approval)
• Doxepin 3 mg or 6 mg (Silenor, FDA-approved for sleep maintenance insomnia) [6]
• Zolpidem IR or ER (generic, Schedule IV, FDA-approved) [7]

A prescriber note documenting adverse effects, contraindications, or lack of response to those agents is the strongest lever for bypassing step therapy. The FDA's guidance on step therapy in Medicare Advantage (which some employer plans adopt voluntarily) states that step therapy exceptions must be granted when a patient has already tried and failed the required alternative or when the alternative is contraindicated [8].

Prior Authorization Checklist

Physicians submitting a PA for Dayvigo should include:

1. DSM-5 diagnosis of chronic insomnia disorder (G47.00 ICD-10)
2. Duration of symptoms (must typically exceed 3 months)
3. Documentation of CBT-I referral or completion, or documented barriers to access
4. Names, doses, durations, and outcomes of prior medication trials
5. Clinical rationale for choosing a DORA over alternatives (e.g., dependency risk with benzodiazepines, morning sedation, comorbid OSA where respiratory depression is a concern)

Plans approved by the Affordable Care Act must issue PA decisions within 72 hours for urgent requests and 15 calendar days for standard requests under the new CMS Interoperability and Prior Authorization Rule effective January 1, 2026 [8].

ICHRA and Dayvigo: A Practical Walkthrough

An Individual Coverage Health Reimbursement Arrangement (ICHRA) lets employers of any size reimburse employees tax-free for individual health insurance premiums and, depending on plan design, for qualifying medical expenses including prescription copays [9].

How ICHRA Reimburses Dayvigo Costs

ICHRA reimbursement for Dayvigo can happen in two ways:

Premium reimbursement path. An employee enrolled in an individual market plan (on or off Exchange) that covers Dayvigo receives ICHRA funds to offset monthly premiums. The out-of-pocket copay at the pharmacy is then governed by that individual plan's benefit design.

Substantiated expense path. If the employer's ICHRA document allows reimbursement of Section 213(d) medical expenses, the employee can submit Dayvigo copay receipts for direct tax-free reimbursement. The IRS defines prescription drug costs as qualifying medical expenses under Section 213(d) [10].

Choosing an Individual Plan That Covers Dayvigo

Not every ACA marketplace plan lists Dayvigo on its formulary. Before selecting a plan during open enrollment:

1. Go to the carrier's drug lookup tool and search "lemborexant."
2. Note the tier, co-pay, and whether PA is required.
3. Calculate your annual break-even: (monthly ICHRA allowance) minus (monthly premium) minus (estimated Dayvigo copay after deductible).

Employees whose ICHRA allowance does not fully cover their premium may claim a premium tax credit only for the portion not covered by the ICHRA, subject to affordability rules finalized in the 2021 IRS Notice 2021-31 [9].

ICHRA and Schedule IV Controlled Substances

Dayvigo is a Schedule IV controlled substance under the Controlled Substances Act [1]. ICHRA reimbursement is not restricted by DEA schedule; the eligibility criterion is whether the expense is a valid Section 213(d) medical expense, which Schedule IV prescription drugs satisfy [10]. The reimbursement process is identical to any other prescription.

How to Get Dayvigo Cheaper: Every Savings Lever Explained

For patients without adequate coverage, or those stuck in a deductible phase, four main options reduce the cash burden.

Eisai Co-Pay Savings Card

Eisai's Dayvigo co-pay savings program (as of 2026) allows eligible commercially insured patients to pay as little as $15 per fill, with a maximum annual savings of approximately $3,600. Eligibility requirements:

• Must have commercial (private) insurance; not valid for patients using Medicare, Medicaid, or any federal- or state-funded program
• Must reside in the United States
• Prescription must be for an FDA-approved indication

The card can be activated at Eisai's patient support portal or by calling 1-888-42-EISAI. The prescriber's office can also enroll the patient during the visit.

Patient Assistance Programs

Eisai operates a patient assistance program (PAP) for uninsured or underinsured patients who meet income thresholds. Income limits are updated annually; in prior years Eisai has used 400 to 600% of the federal poverty level as a cutoff. The program provides Dayvigo at no charge or significantly reduced cost and is accessible through Eisai's Oncology and CNS patient support line or through NeedyMeds (needymeds.org).

Manufacturer-Independent Discount Cards

GoodRx, RxSaver, and similar pharmacy benefit discount cards can reduce the cash price of Dayvigo to approximately $350, $400 at high-volume pharmacies. These cards cannot be combined with insurance co-pays or Eisai's co-pay card, so they are most useful for patients who are uninsured or in a high-deductible plan before meeting the deductible.

90-Day Mail-Order Fills

Many employer plans and individual ACA plans offer a lower per-fill cost for 90-day supplies through mail-order pharmacies. A patient paying $75 per 30-day fill at retail may pay $150 for a 90-day mail-order supply, effectively saving $75 per quarter. Confirm with your plan's pharmacy benefit manager whether Dayvigo qualifies for 90-day dispensing; Schedule IV controlled substances are legal to dispense for 90 days in most states.

HSA and FSA Eligibility for Dayvigo

Dayvigo qualifies as an HSA- and FSA-eligible expense. The IRS designates prescription drug costs as qualified medical expenses under Section 213(d) of the Internal Revenue Code [10]. You can use pre-tax HSA or FSA dollars to pay for:

• Dayvigo copays or coinsurance
• Full cash price if uninsured
• Mail-order pharmacy charges

HSA funds roll over indefinitely. FSA funds are subject to the use-it-or-lose-it rule, though most employers offer a 2.5-month grace period or a $640 rollover option (2026 IRS limit) [10]. If your deductible phase hits mid-year and your FSA is nearly exhausted, stacking the Eisai co-pay card on top of your insurance co-pay (not on the FSA-paid portion) is not permitted; however, you can use your FSA to pay the Eisai-reduced co-pay of $15.

Navigating a Coverage Denial

How to Appeal

If your employer plan denies Dayvigo, you have the right to a formal internal appeal under the ACA's appeals and external review requirements [11]. The appeal letter should:

1. Reference the specific denial reason (e.g., step therapy not completed, not medically necessary)
2. Include a letter from your prescribing physician explaining clinical necessity
3. Cite the AASM 2023 guideline if CBT-I was attempted or is inaccessible [4]
4. Include any peer-reviewed evidence on lemborexant safety compared with benzodiazepines (relevant if the denial cited "comparable alternatives") [2]

If the internal appeal fails, you can request an Independent Medical Review (IMR) or external review. ACA-compliant plans must provide external review through an accredited Independent Review Organization, and these reviews result in overturns roughly 40 to 60% of the time for brand-name sleep medications in published analyses [11].

Step Therapy Bypass Language

Several states (including New York, Texas, and Illinois as of 2026) have enacted step therapy reform laws requiring that plans grant exceptions when a patient's prescriber documents that the required step-therapy drug is contraindicated, is expected to cause harm, or was previously tried without benefit [12]. If your state has such a law and your plan is a fully insured group plan (not ERISA self-insured), your prescriber can invoke the state exception process directly. ERISA self-insured plans are generally not subject to state step therapy laws, though many carriers voluntarily adopt similar exception processes.

The HealthRX Access Framework for Dayvigo organizes the coverage navigation into three tiers:

• Tier 1 (fastest path): PA approval on first submission using the full checklist above. Target: 15 calendar days.
• Tier 2 (fallback): Eisai co-pay card activated simultaneously with PA submission so the first fill is affordable regardless of approval timing.
• Tier 3 (denial path): Internal appeal plus state step therapy exception (if applicable), with PAP enrollment as a bridge during the appeal window.

Clinical Safety Context Prescribers Should Document

Documenting Dayvigo's clinical safety profile in the PA letter strengthens the medical necessity argument, particularly when the plan's preferred alternative is a benzodiazepine or a non-benzodiazepine GABA-A modulator (Z-drug).

Dependence and Abuse Potential

The FDA's pharmacology review for lemborexant notes that the orexin receptor mechanism carries a lower theoretical abuse potential than GABA-A modulators because it does not produce global CNS depression [1]. The SUNRISE-1 trial (N=291) assessed next-morning residual sedation and found that lemborexant 10 mg produced less driving impairment 9 hours post-dose than zolpidem extended-release 6.25 mg (P<0.05) [13].

Respiratory Safety

Lemborexant does not cause clinically significant respiratory depression at therapeutic doses, an advantage in patients with mild-to-moderate obstructive sleep apnea. The FDA label states that the drug has not been studied in patients with severe OSA and should be used with caution in that population [1]. A 2020 post-marketing study published in Sleep Medicine Reviews concluded that DORAs as a class have a more favorable respiratory profile than benzodiazepines in patients with comorbid sleep-disordered breathing [14].

Drug Interactions to Flag in PA Letters

Lemborexant is a CYP3A4 substrate. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase lemborexant exposure and are contraindicated with the 10 mg dose. Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) reduce efficacy significantly; concurrent use is not recommended [1]. Documenting that a patient's medication list creates a CYP3A interaction with zolpidem or another step-therapy drug is a valid basis for a step-therapy exception.

Switching From Another Sleep Medication to Dayvigo

Patients transitioning from zolpidem, eszopiclone, or suvorexant do not require a washout period for Dayvigo, but prescribers should taper the prior agent to avoid rebound insomnia. The AASM 2023 guideline recommends a gradual taper over 2 to 4 weeks for benzodiazepines and Z-drugs rather than abrupt discontinuation [4]. Insurance plans may require documentation of the ongoing taper to approve the overlap period when both drugs appear on pharmacy claims.

For patients switching from suvorexant (Belsomra) to lemborexant, the PA letter should note the clinical rationale, such as superior performance on sleep onset latency measures in the SUNRISE-2 trial vs. Historical suvorexant data, or a specific tolerability issue [3].

Frequently Asked Questions